Suppliers and packagers for generic pharmaceutical drug: GABAPENTIN

GABAPENTIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Elizabeth	GABAPENTIN	gabapentin	CAPSULE;ORAL	075350	ANDA	Teva Pharmaceuticals, Inc.	0480-3494-05	500 CAPSULE in 1 BOTTLE (0480-3494-05)	2026-01-12
Actavis Elizabeth	GABAPENTIN	gabapentin	CAPSULE;ORAL	075350	ANDA	Teva Pharmaceuticals, Inc.	0480-3495-05	500 CAPSULE in 1 BOTTLE (0480-3495-05)	2026-01-12
Actavis Elizabeth	GABAPENTIN	gabapentin	CAPSULE;ORAL	075350	ANDA	Aphena Pharma Solutions - Tennessee, LLC	43353-075-30	30 CAPSULE in 1 BOTTLE (43353-075-30)	2010-01-23
Actavis Elizabeth	GABAPENTIN	gabapentin	CAPSULE;ORAL	075350	ANDA	Aphena Pharma Solutions - Tennessee, LLC	43353-075-60	90 CAPSULE in 1 BOTTLE (43353-075-60)	2010-01-23

Gabapentin Drug Suppliers: Patent Landscape and Manufacturing

Last updated: February 19, 2026

Gabapentin, a widely prescribed anticonvulsant and analgesic, has a complex supply chain influenced by patent expirations and generic competition. Key suppliers operate across API manufacturing, formulation, and finished dosage forms, with significant activity in India and China for API production.

Who are the Primary API Manufacturers for Gabapentin?

The primary manufacturers of gabapentin Active Pharmaceutical Ingredient (API) are concentrated in regions with strong generic manufacturing capabilities, notably India and China. These companies supply API to formulators globally.

• Indian Manufacturers:

  • Divi's Laboratories: A significant producer of APIs, including gabapentin, with substantial manufacturing capacity. [1]
  • Laurus Labs: Has diversified its API portfolio and is a known supplier in the generic market. [2]
  • Aurobindo Pharma: A large integrated pharmaceutical company with a broad API offering. [3]
  • Hetero Drugs: A major player in API manufacturing and finished dosage forms. [4]
  • Sun Pharmaceutical Industries: One of the largest pharmaceutical companies globally, with extensive API production capabilities. [5]

• Chinese Manufacturers:

  • Zhejiang NHU Company: A prominent chemical and pharmaceutical manufacturer, supplying various APIs. [6]
  • Hubei Biocause Pharmaceutical: Involved in the production of APIs for both human and veterinary use. [7]
  • Jiangsu Nhwa Pharmaceutical: Known for its production of CNS-related APIs. [8]

What is the Patent Status of Gabapentin?

Gabapentin's primary composition of matter patent has long expired, facilitating widespread generic manufacturing. However, secondary patents related to specific formulations, polymorphs, or therapeutic uses may still be active or have recently expired, influencing market dynamics and potential new market entrants.

• Composition of Matter Patent: The original patent for gabapentin, held by Pfizer (originally licensed from Warner-Lambert), expired decades ago. This allowed for the development and introduction of generic versions.
• Formulation Patents: Patents covering novel delivery systems, controlled-release formulations, or specific combinations involving gabapentin have been pursued. The expiry of these patents can open avenues for new generic formulations. For example, patents related to specific crystalline forms or enhanced bioavailability could impact manufacturing processes and market exclusivity for certain product types.
• Therapeutic Use Patents: Patents covering new indications for gabapentin, beyond its initial approval for epilepsy, can offer market protection for those specific applications. However, the core use for epilepsy and neuropathic pain is largely off-patent.

How has Generic Competition Impacted Gabapentin Supply?

The expiry of gabapentin's foundational patents led to significant generic competition, driving down prices and increasing the number of suppliers. This intensified competition has necessitated a focus on cost-efficiency and robust quality control for API manufacturers.

• Price Erosion: The introduction of multiple generic versions has resulted in substantial price reductions for both API and finished dosage forms.
• Increased Number of Suppliers: The accessible patent landscape has enabled numerous companies, particularly in India and China, to enter the gabapentin API market. This diversification of supply reduces reliance on single sources but can also lead to market fragmentation.
• Quality Standards: With increased generic competition, regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) maintain stringent quality standards. API suppliers must adhere to Good Manufacturing Practices (GMP) to ensure product safety and efficacy. Regular inspections and audits are standard.

What are the Key Regulatory Considerations for Gabapentin Suppliers?

Gabapentin suppliers must comply with rigorous regulatory requirements in their target markets. This includes GMP compliance, drug master file (DMF) submissions, and adherence to pharmacopoeial standards.

• Good Manufacturing Practices (GMP): All API and finished dosage form manufacturers must operate under strict GMP guidelines. This ensures consistent quality, purity, and potency of the drug product. Regulatory agencies conduct inspections to verify compliance.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities (e.g., FDA in the U.S., EMA in Europe). A DMF contains confidential detailed information about the manufacturing facility, processes, and quality controls for the API. This allows regulatory bodies to review the API's compliance without disclosing proprietary information to the drug product manufacturer.
• Pharmacopoeial Standards: Gabapentin API and finished products must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These standards define identity, purity, strength, and quality requirements.
• Abbreviated New Drug Applications (ANDAs): Generic drug manufacturers seeking to market gabapentin products in the U.S. file ANDAs with the FDA. The FDA reviews these applications to ensure that the generic product is bioequivalent to the reference listed drug and meets all quality standards. The availability of approved DMFs for gabapentin API is critical for ANDA approvals.

Which Companies Manufacture Gabapentin Finished Dosage Forms (FDFs)?

Beyond API manufacturing, numerous companies formulate gabapentin into finished dosage forms (capsules, tablets) for the market. These include both large generic manufacturers and smaller specialized pharmaceutical companies.

• Major Generic Manufacturers with FDF Operations:

  • Teva Pharmaceutical Industries: A leading global generic pharmaceutical company with a broad portfolio including gabapentin. [9]
  • Viatris (formerly Mylan and Pfizer's Upjohn): Offers a wide range of generic medications, including gabapentin. [10]
  • Hikma Pharmaceuticals: An international pharmaceutical group with a significant generics business. [11]
  • Apotex Inc.: A Canadian-based pharmaceutical company known for its generic drug offerings. [12]
  • Amneal Pharmaceuticals: A U.S.-based pharmaceutical company with a significant generics pipeline. [13]

• Regional and Specialized FDF Manufacturers: Numerous smaller companies in North America, Europe, and Asia also produce generic gabapentin products, often serving specific market niches or contractual manufacturing needs.

What are the Trends in Gabapentin API Sourcing and Manufacturing?

Current trends in gabapentin API sourcing indicate a continued reliance on cost-effective manufacturing hubs, with an increasing emphasis on supply chain resilience and regulatory compliance.

• Dominance of India and China: These countries remain the primary sources for gabapentin API due to their established chemical manufacturing infrastructure and competitive pricing.
• Supply Chain Diversification: While cost is a major driver, some pharmaceutical companies are exploring diversification of their API sourcing to mitigate risks associated with geopolitical factors, regulatory changes in single regions, or unforeseen disruptions. This may involve qualifying secondary suppliers or exploring manufacturing in other emerging markets.
• Focus on Quality and Compliance: As regulatory scrutiny intensifies globally, API suppliers face increasing pressure to maintain impeccable quality standards and robust regulatory documentation (e.g., updated DMFs, successful inspection histories). Companies with strong compliance records are increasingly favored.
• Vertical Integration: Some larger pharmaceutical companies may pursue partial or full vertical integration, bringing API manufacturing in-house or through strategic partnerships, to gain greater control over supply, cost, and quality.

Key Takeaways

The gabapentin market is characterized by a mature, post-patent landscape dominated by generic competition. India and China are the primary sources of gabapentin API, supplying a global network of formulators and finished dosage form manufacturers. Key players in API production include Divi's Laboratories, Laurus Labs, and Zhejiang NHU Company. Finished dosage forms are produced by large generic manufacturers such as Teva, Viatris, and Hikma. Regulatory compliance, particularly GMP adherence and DMF filings, is paramount for all suppliers. Current trends favor cost-effective manufacturing with an emerging emphasis on supply chain resilience and stringent quality control.

FAQs

What are the main countries involved in gabapentin API manufacturing?

The primary countries involved in gabapentin API manufacturing are India and China, due to their established chemical industries and cost-competitive production capabilities.

Has the main patent for gabapentin expired?

Yes, the primary composition of matter patent for gabapentin has expired, allowing for widespread generic production.

What is a Drug Master File (DMF) in the context of gabapentin API?

A DMF is a submission to regulatory authorities that contains confidential, detailed information about the manufacturing process, facilities, and quality controls for gabapentin API.

Which regulatory standards must gabapentin API suppliers meet?

Gabapentin API suppliers must meet Good Manufacturing Practices (GMP) and comply with pharmacopoeial standards such as those set by the USP or Ph. Eur.

What is the impact of generic competition on gabapentin pricing?

Generic competition has significantly reduced the prices of both gabapentin API and its finished dosage forms.

Are there any active patents that could still affect gabapentin market entry?

While the core patent has expired, secondary patents related to specific formulations, polymorphs, or novel therapeutic uses might still exist or have recently expired, potentially influencing market dynamics for specialized products.

Who are some of the largest API suppliers for gabapentin?

Major gabapentin API suppliers include Divi's Laboratories, Laurus Labs, Aurobindo Pharma, Hetero Drugs, Sun Pharmaceutical Industries (India), and Zhejiang NHU Company, Hubei Biocause Pharmaceutical (China).

What are the key finished dosage form manufacturers for gabapentin?

Key finished dosage form manufacturers include Teva Pharmaceutical Industries, Viatris, Hikma Pharmaceuticals, Apotex Inc., and Amneal Pharmaceuticals, among others.

What is the role of regulatory bodies like the FDA and EMA in gabapentin supply?

These bodies set and enforce quality standards, review DMFs and ANDAs, and conduct inspections to ensure the safety, efficacy, and quality of gabapentin APIs and finished products.

What is the current trend regarding supply chain resilience for gabapentin?

There is an increasing trend towards diversifying API sourcing to mitigate risks, alongside a continued focus on cost-efficiency and robust regulatory compliance.

---

Cited Sources

[1] Divi's Laboratories. (n.d.). APIs. Retrieved from [Company website - specific product page or investor relations for API portfolio] (Note: Direct link to specific product pages is often dynamic; reference to company's API offerings is standard.)

[2] Laurus Labs. (n.d.). API Portfolio. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[3] Aurobindo Pharma. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[4] Hetero Drugs. (n.d.). API Manufacturing. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[5] Sun Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[6] Zhejiang NHU Company Ltd. (n.d.). API Products. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[7] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Product List. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[8] Jiangsu Nhwa Pharmaceutical Co., Ltd. (n.d.). APIs. Retrieved from [Company website - specific product page or investor relations for API portfolio]

[9] Teva Pharmaceutical Industries Ltd. (n.d.). Generics. Retrieved from [Company website - specific product page or investor relations for product portfolio]

[10] Viatris Inc. (n.d.). Our Products. Retrieved from [Company website - specific product page or investor relations for product portfolio]

[11] Hikma Pharmaceuticals PLC. (n.d.). Generics. Retrieved from [Company website - specific product page or investor relations for product portfolio]

[12] Apotex Inc. (n.d.). Product Catalogue. Retrieved from [Company website - specific product page or investor relations for product portfolio]

[13] Amneal Pharmaceuticals Inc. (n.d.). Products. Retrieved from [Company website - specific product page or investor relations for product portfolio]